Rethinking Nano Drug Design
Researchers may have made some incorrect assumptions about how to design nanoparticles deliver drugs that target tumor cells, according to preliminary research presented this week at the 2009 Materials Research Society Spring Meeting in San Francisco.
Most of the nanoparticle “envelopes” used to encapsulate cancer drugs rely on two mechanisms to get to their destination. The drugs are coated in these envelopes so that they cannot pass through healthy blood vessels into healthy tissues but can pass through the holes in leaky blood vessels that feed tumors. But this is no guarantee that the tumors will take up the drug, which might continue circulating in the blood. To make the targeting more specific, the outside of these envelopes are often decorated with molecules that are recognized by receptors present in large numbers on the surfaces of tumor cells. Chemists usually load the nanoparticles with these tumor-specific molecules, according MIT chemical engineering professor Paula Hammond, whom I caught up with at the conference. “The assumption is, if you increase the [number of places to bind], you increase the drug uptake,” she says.
But Hammond presented preliminary results suggesting that the number of targeting molecules isn’t the only important factor in getting a tumor to take up a drug; their arrangement is also important. Hammond compared drug uptake when the targeting molecules were loaded all over the nanoparticle envelope, and when they were clustered in patches, as they are on biological cells. “We found that we can greatly influence how much tumors take up by changing the size of the patches, and that drug uptake goes down if there are too many patches.”
Keep Reading
Most Popular

The dark secret behind those cute AI-generated animal images
Google Brain has revealed its own image-making AI, called Imagen. But don't expect to see anything that isn't wholesome.

The hype around DeepMind’s new AI model misses what’s actually cool about it
Some worry that the chatter about these tools is doing the whole field a disservice.

The walls are closing in on Clearview AI
The controversial face recognition company was just fined $10 million for scraping UK faces from the web. That might not be the end of it.

This horse-riding astronaut is a milestone in AI’s journey to make sense of the world
OpenAI’s latest picture-making AI is amazing—but raises questions about what we mean by intelligence.
Stay connected

Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.